Epirubicin Hydrochloride: Brands, Price & Uses in Bangladesh

Epirubicin Hydrochloride is a cytotoxic anthracycline antibiotic used in cancer chemotherapy, almost always as part of a combination regimen.

Established / FDA-approved use

• As a component of adjuvant chemotherapy in patients with early breast cancer who have evidence of axillary lymph node involvement following surgical resection of the primary tumor, typically combined with other agents such as cyclophosphamide and fluorouracil.

Guideline-supported / widely used combination-regimen indications

• Metastatic or advanced breast cancer, as part of combination chemotherapy.
• Advanced gastric (stomach) cancer, in combination regimens (e.g., with cisplatin and fluorouracil).

Off-label uses (less common, individualized by an oncologist)

• Selected soft-tissue sarcomas, ovarian cancer, and certain lymphomas, when used by specialists as part of protocol-based combination chemotherapy.
• Intravesical (bladder instillation) use for superficial (non-muscle-invasive) bladder cancer or carcinoma in situ, and for prophylaxis after resection, in specific formulations intended for this route.

Epirubicin Hydrochloride must only be prescribed and administered by, or under the supervision of, a physician experienced in the use of cytotoxic chemotherapy.

Epirubicin Hydrochloride is given exclusively by a healthcare professional, under the supervision of a physician experienced in cytotoxic chemotherapy. Dosing is individualized based on the specific regimen, indication, body surface area, and the patient's hematologic and hepatic status.

Dose adjustments

• Hepatic impairment: Dose reduction (approximately 50% for moderate elevation of bilirubin/AST, and up to 75% for marked elevation) is required, as hepatic impairment significantly increases toxicity; see Use in Special Populations.
• Bone marrow suppression: Doses are withheld or reduced if blood counts have not recovered to acceptable levels before the next cycle; see Precautions and Side Effects.
• Cumulative dose: A lifetime cumulative dose ceiling is observed to limit the risk of irreversible cardiotoxicity; see Precautions and Warnings.

Do not attempt to self-administer Epirubicin Hydrochloride; it is administered only in a hospital or clinic setting equipped to manage chemotherapy and its complications.

Side effects of Epirubicin Hydrochloride are frequent and dose-related, given that it is a potent cytotoxic chemotherapy agent. Report any severe or persistent symptom to your treating team immediately.

Very common

• Myelosuppression (low white blood cells, anemia, low platelets) — increases infection and bleeding risk.
• Nausea, vomiting, mucositis/stomatitis, diarrhea.
• Alopecia (hair loss), usually reversible after treatment ends.
• Amenorrhea (in women) and effects on fertility.
• Reddish discoloration of urine for 1–2 days after administration (expected, not harmful).

Serious (require prompt medical attention)

• Signs of heart failure/cardiotoxicity (shortness of breath, swelling of legs, irregular heartbeat) — see Precautions and Warnings.
• Severe or prolonged fever, chills, or signs of infection due to low white cell counts.
• Injection-site pain, redness, or tissue damage from extravasation.
• Signs of secondary blood cancers (unusual bruising, persistent fatigue), which can occur months to years after treatment — see Precautions and Warnings.